...
首页> 外文期刊>Inflammopharmacology >Aberrant up-regulation ofiNOS/NO system is correlated with an increased abundance of Foxp3(+)cells and reduced effector/memory cell markers expression during colorectal cancer: immunomodulatory effects of cetuximab combined with chemotherapy
【24h】

Aberrant up-regulation ofiNOS/NO system is correlated with an increased abundance of Foxp3(+)cells and reduced effector/memory cell markers expression during colorectal cancer: immunomodulatory effects of cetuximab combined with chemotherapy

机译:异常上调/无系统与富抗症3(+)细胞的丰度和结肠直肠癌中的减少的效应/记忆细胞标志物表达相关:西妥昔单抗与化疗相结合的免疫调节作用

获取原文
获取原文并翻译 | 示例

摘要

Colorectal cancer (CRC) remains the most cancer type related to chronic inflammation; however, the mechanisms that link inflammation to CRC development and progression are still poorly understood. Our study aimed to investigate one of the prominent inflammatory response in cancers, iNOS/NO system. In this regard, we evaluated the link between the iNOS/NO system and CRC progression, its relation with the host immune responses and its response to cetuximab combined with chemotherapy. We found that the nitrite levels were nearly twice as highin metastatic CRC plasma and culture supernatants from PBMCs and tumor explants compared with those without metastases and healthy controls. Interestingly, we showed that the highest iNOS expression and NO levels are present in the damaged CRC tissues that have highest leukocyte infiltration. Our findings highlight the implication of iNOS/NO system in tissue alteration and leukocyte invasion. Thus, we observed imbalance between effector/memory T cell markers and Treg transcription factor (Foxp3). Accordingly, we detected higher IFN gamma and T-bet expression levels in colorectal tumor tissuesatearly stage. In contrast, consistent withiNOS and Foxp3 expression, TGF beta, CTLA-4 and IL-10 were significantly related to the tumor stage progression. Furthermore, our study revealed that Cetuximab combined with chemotherapy treatment markedly down-regulates iNOS/NO system as well as IL-10 and TGF beta levels. Altogether, we conclude that cetuximab can potentiate the efficacy of chemotherapy, particularly by iNOS/NO system and immunosuppressive cytokines modulation. Thus, we suggest that iNOS/NO system may represent an attractive candidate biomarker for monitoring CRC progression, malignity and response to therapy.
机译:结肠直肠癌(CRC)仍然是与慢性炎症有关的最多癌症类型;然而,将炎症与CRC开发和进展联系起来的机制仍然很差。我们的研究旨在调查癌症,Inos / No System中突出的炎症反应之一。在这方面,我们评估了INOS / NO系统和CRC进展之间的联系,其与宿主免疫应答的关系及其对西妥昔单抗与化疗的反应。我们发现,与没有转移和健康对照的那些,亚硝酸盐水平几乎是PBMC和肿瘤外植物的培养物和肿瘤外植物。有趣的是,我们表明,在具有最高白细胞浸润的受损的CRC组织中存在最高的InOS表达和没有水平。我们的研究结果强调了Inos / No System在组织改变和白细胞侵袭中的含义。因此,我们观察到效应/内存T细胞标记物和Treg转录因子(Foxp3)之间的不平衡。因此,我们检测到更高的IFNγ和T-BET表达水平在结肠直肠肿瘤组织阶段。相比之下,一致的内部内部和FoxP3表达,TGFβ,CTLA-4和IL-10与肿瘤阶段的进展显着相关。此外,我们的研究表明,西妥昔单抗结合化疗治疗明显下调INOS / NO系统以及IL-10和TGFβ水平。总之,我们得出结论,西妥昔单抗可以提高化疗的疗效,特别是通过Inos / No System和免疫抑制细胞因子调节。因此,我们建议Inos / No System可以代表一个有吸引力的候选生物标志物,用于监测CRC进展,恶性性和对治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号